EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BST2 and DIRAS3 Drive Immune Evasion and Tumor Progression in High-Grade Glioma

Zhangjun Liao, Shuyi Wu iD, Zhenyi Shi, Donghui Chen, Jinrui Chen, Hua Zhang

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26136205 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Zhangjun Liao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, School of Medical Technology, Guangdong Medical University, Dong…. Hauptthemen laut MEDLINE: Glioma, Antigens, CD, GPI-Linked Proteins, Brain Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Guangdong Province, Key Discipline Construction Project of Guangdong Medical University, National Undergraduate Training Program for Innovation and Entrepreneurship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High-grade gliomas (HGGs, WHO grades 3–4) are highly aggressive, with a poor prognosis and treatment resistance. Immune evasion may contribute to their progression, but the role of cytotoxic T-lymphocyte immune evasion (CTLE) is not well-validated. This study analyzed the transcriptomic data of 525 patients from TCGA-GBM-HG_U133A. Two molecular subtypes were identified based on 182 CTLE-associated genes, with 238 differentially expressed genes between them. A prognostic model was developed, identifying BST2 and DIRAS3 as key risk factors, and validated in multiple cohorts. The subtypes had distinct immune profiles, with Cluster 2 showing higher immune infiltration but a poorer prognosis. The model had a good predictive performance. High-risk patients had upregulated BST2 and DIRAS3, linked to immunosuppression and shorter survival. Knockdown experiments confirmed their roles in GBM cell migration and invasion. Mechanistically, they promote immune evasion. BST2 and DIRAS3 could be therapeutic targets for HGG immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaAntigens, CDGPI-Linked ProteinsBrain NeoplasmsImmune EvasionTumor EscapeHumansDisease ProgressionGene Expression Regulation, NeoplasticPrognosisCell Line, TumorCell MovementMaleFemaleNeoplasm GradingBone Marrow Stromal Antigen 2

Stichwörter der Autor:innen

BST2DIRAS3cytotoxic T lymphocyteshigh-grade gliomasprognostic model

Substanzen

BST2 protein, humanAntigens, CDGPI-Linked ProteinsBone Marrow Stromal Antigen 2

Autor:innen und Institutionen

  • Guangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, School of Medical Technology, Guangdong Medical University, Dongguan 523808, China.

ORCID-Profile: Shuyi Wu

Förderung

  • Natural Science Foundation of Guangdong Province
  • Key Discipline Construction Project of Guangdong Medical University
  • National Undergraduate Training Program for Innovation and Entrepreneurship

Zitieren

APA

Liao, Z., Wu, S., Shi, Z., Chen, D., Chen, J., & Zhang, H. (2025). BST2 and DIRAS3 Drive Immune Evasion and Tumor Progression in High-Grade Glioma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26136205

Vancouver

Liao Z, Wu S, Shi Z, Chen D, Chen J, Zhang H. BST2 and DIRAS3 Drive Immune Evasion and Tumor Progression in High-Grade Glioma. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26136205

BibTeX
@article{Liao2025,
  author = {Liao, Zhangjun and Wu, Shuyi and Shi, Zhenyi and Chen, Donghui and Chen, Jinrui and Zhang, Hua},
  title = {BST2 and DIRAS3 Drive Immune Evasion and Tumor Progression in High-Grade Glioma},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26136205}
}
Kostenlos starten →